Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Dova Pharmaceuticals, Inc. (DOVA) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/12/2019 8-K Quarterly results
10/03/2019 8-K Quarterly results
09/30/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "Dova Pharmaceuticals to be Acquired by Swedish Orphan Biovitrum AB"
08/06/2019 8-K Quarterly results
Docs: "Dova Pharmaceuticals Reports Second Quarter 2019 Operating and Financial Results"
06/27/2019 8-K Quarterly results
05/07/2019 8-K Quarterly results
Docs: "Dova Pharmaceuticals Reports First Quarter 2019 Operating and Financial Results"
04/26/2019 8-K Submission of Matters to a Vote of Security Holders
03/05/2019 8-K Quarterly results
Docs: "Dova Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Operating and Financial Results DOPTELET ® approved May 21, 2018 and launched June 4, 2018 Net product sales from DOPTELET were $2.8 million in the fourth quarter of 2018 and $7.7 million for the full year ended December 31, 2018 sNDA accepted for review by FDA for DOPTELET for the treatment of chronic immune thrombocytopenia with a PDUFA goal date of June 30, 2019 Appointed Dr. David Zaccardelli as President and Chief Executive Officer and Jason Hoitt as Chief Commercial Officer Conference call scheduled for 9:00 a.m. ET today"
02/08/2019 8-K Quarterly results
01/07/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Company Presentation"
12/20/2018 8-K Results of Operations and Financial Condition, Departure of Directors or Certain Officers; Election of Directors; Appointment...
Docs: "Amended and Restated 2017 Equity Incentive Plan, as amended",
"Form of Restricted Stock Unit Grant Notice and Award Agreement",
"Second Amended and Restated Non-Employee Director Compensation Policy",
"Dova Pharmaceuticals Announces Management Changes"
10/04/2018 8-K Entry into a Material Definitive Agreement
10/02/2018 8-K Quarterly results
09/27/2018 8-K Quarterly results
08/09/2018 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Dova Pharmaceuticals Reports Second Quarter 2018 Operating and Financial Results"
07/27/2018 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "At-the-Market Equity Offering Sales Agreement, by and between Dova Pharmaceuticals, Inc. and Stifel, Nicolaus & Company, Incorporated"
06/25/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Nancy J. Wysenski Joins Dova Pharmaceuticals' Board of Directors"
06/20/2018 8-K Submission of Matters to a Vote of Security Holders
05/24/2018 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Office Lease Agreement, by and between the Registrant and Pine Forest 240 TT, LLC"
05/21/2018 8-K Investor presentation
Docs: "Dova Pharmaceuticals Announces U.S. FDA Approval of DOPTELET®",
"Presentation"
05/09/2018 8-K Quarterly results
Docs: "Dova Pharmaceuticals Reports First Quarter 2018 Operating and Financial Results"
04/20/2018 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
04/03/2018 8-K Termination of a Material Definitive Agreement
03/27/2018 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
Docs: "Letter from KPMG LLP"
03/15/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/15/2018 8-K Quarterly results
Docs: "Dova Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Operating and Financial Results"
01/31/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment Agreement, by and between the Company and Mark W. Hahn"
11/28/2017 8-K Other Events, Financial Statements and Exhibits
Docs: "Dova Pharmaceuticals Announces FDA Acceptance of the Avatrombopag New Drug Application with Priority Review"
11/09/2017 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Dova Pharmaceuticals Reports Third Quarter 2017 Operating and Financial Results"
10/23/2017 8-K Quarterly results
09/22/2017 8-K Quarterly results
08/10/2017 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Dova Pharmaceuticals Reports Second Quarter 2017 Operating and Financial Results"
07/05/2017 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy